In Brief: Sunrise Technologies/American Dental Technologies
This article was originally published in The Gray Sheet
Sunrise Technologies/American Dental Technologies: Firms jointly announce settlement of all pending lawsuits between the two firms. Under terms of the settlement, Sunrise will not require ADT to pay $940,179 awarded to Sunrise in October 1995 as the result of a 1993 breach of contract dispute between the two firms; ADT also agrees to drop its appeal in the case. In addition, both firms agree to cease patent infringement suits and countersuits related to their dental air abrasive patents ("The Gray Sheet" Nov. 21, 1994, p. 13). Sunrise will license ADT's patents in a non-exclusive basis in return for royalty payments "on air abrasive products manufactured, sold or leased by Sunrise." Both firms also acknowledge the validity and non-infringing basis of each other's air abrasive patents...
You may also be interested in...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.